Carl Barnes Heilman MD
Professor and Chair, Neurosurgery, Tufts Medical Center
Join to View Full Profile
800 Washington StTufts Medical Center, #178 NeurosurgeryBoston, MA 02111
Phone+1 617-636-5860
Fax+1 617-636-7587
Dr. Heilman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tufts Medical CenterResidency, Neurological Surgery, 1987 - 1993
St Elizabeth's Medical Center/Lemuel Shattuck HospitalInternship, Transitional Year, 1986 - 1987
Perelman School of Medicine at the University of PennsylvaniaClass of 1986
Certifications & Licensure
MA State Medical License 1988 - 2025
PA State Medical License 1991 - 1992
American Board of Neurological Surgery Neurological Surgery
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2007-2014
- Boston Magazine Castle Connolly, 2008-2013
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Join now to see all
Publications & Presentations
PubMed
- Techniques for Repairing Tegmen Defects When the Ossicles Protrude Above the Floor of the Middle Fossa.Jacob Kosarchuk, Maria Majid, Sydney Ho, Kathryn Noonan, Jonathon Sillman
Journal of Neurological Surgery Reports. 2025-07-01 - Endovascular Cerebrospinal Fluid Diversion with the eShunt: Bridging Adult Trials to Pediatrics.Marco Colasurdo, Adel M Malek, Carl B Heilman, Peter Kan
World Neurosurgery. 2025-06-10 - Stent Retriever and Aspiration Catheter Biopsy of an Intraluminal Transverse Sinus Meningioma: Case Report.Alper Dincer, M Harrison Snyder, Shane M Burke, Knarik Arkun, Carl B Heilman
Operative Neurosurgery. 2025-04-21
Authored Content
- Regression of a Nonfunctioning Pituitary Macroadenoma on the CDK4/6 Inhibitor Palbociclib: Case Report RelatedJune 2018
Press Mentions
CereVasc Receives Health Canada Investigational Testing Authorization for STRIDE Clinical Trial of the eShunt® SystemJune 19th, 2025- CereVasc, Inc. Receives FDA Breakthrough Device Designation for the eShunt® System for Use in Pediatric PatientsApril 23rd, 2025
- From Student to LeaderFebruary 6th, 2025
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
